NAT10 and gastric cancer: To further analyze the relationships between NAT10/KLF5 expression and the prognosis of GC patients, IHC staining was performed on a TMA containing 192 GC samples (cohort 2), and the results revealed that the group with high expression of both NAT10 and KLF5 had a significantly worse prognosis than the group with low expression of NAT10 and/or KLF5 (p < 0.001) (Figure 5P); this finding was further confirmed by univariate Cox regression analysis (hazard ratios (HR) = 1.332; 95% confidence interval (CI) (1.188–1.493); p = 9.432e‐07) (Figure S7H, Supporting Information).